GlycoMimetics, Inc. (NASDAQ:GLYC) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On May 8, 2017,GlycoMimetics, Inc. (the Registrant) issued a
press release announcing its financial results for the quarter
ended March 31, 2017. A copy of this press release is furnished
herewith as Exhibit 99.1 to this Current Report and is
incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Item 2.02, and Exhibit 99.1 hereto, shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any of the Registrants filings under
the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof, regardless of any
incorporation language in such a filing, except as expressly set
forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit |
|
|
Number |
ExhibitDescription |
|
99.1 |
Press Release, dated May 8, 2017, GlycoMimetics Reports |
2
About GlycoMimetics, Inc. (NASDAQ:GLYC)
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9. GlycoMimetics, Inc. (NASDAQ:GLYC) Recent Trading Information
GlycoMimetics, Inc. (NASDAQ:GLYC) closed its last trading session up +0.23 at 4.16 with 95,945 shares trading hands.
